Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02045095
Other study ID # C33001
Secondary ID U1111-1203-6359
Status Terminated
Phase Phase 1
First received
Last updated
Start date January 31, 2014
Est. completion date November 9, 2016

Study information

Verified date November 2018
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting toxicities [DLTs]) of MLN7243.


Description:

This is a single arm Phase I study with multiple dosing cohorts as noted below:

- Schedule A: MLN7243 1 mg

- Schedule A: MLN7243 2 mg

- Schedule A: MLN7243 4 mg

- Schedule A: MLN7243 8 mg

- Schedule A: MLN7243 12 mg

- Schedule A: MLN7243 18 mg

- Schedule A: MLN7243 Homozygous Mutant 4 mg


Recruitment information / eligibility

Status Terminated
Enrollment 29
Est. completion date November 9, 2016
Est. primary completion date November 9, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

1. Male or female participants 18 years or older.

2. Participants must have a histologically confirmed diagnosis of an advanced, metastatic malignant solid tumor and must have failed or exhausted standard therapies or for which no standard therapy is available.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Participants with adequate hematologic and organ function.

5. All participants must have radiographically detectable tumors with measurable disease as defined by RECIST (version 1.1).

6. Participants undergoing a biopsy procedure must have accessible lesions which are safe to biopsy.

7. Recovered (that is, less than or equal to (<=) Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy, except alopecia.

8. Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 4 months after the last dose of study drug, or agree to practice true abstinence.

Male participants who agree to practice effective barrier contraception during the entire study treatment period through 4 months after the last dose of study drug or agree to practice true abstinence.

9. Suitable venous access for the study-required blood sampling including PK sampling.

Exclusion Criteria

Participants meeting any of the following exclusion criteria are not to be enrolled in the study:

1. Participants with clinically significant pre-existing cardiac impairment.

2. Participants homozygous for the ABCG2 (BCRP) c.421C greater than (>) 1 A polymorphism will be excluded from the study until the safety of a minimum of the first 3 dose levels has been characterized and the sponsor confirms that such participants can be enrolled at doses that are at least 3-fold lower than the most recently determined safe and tolerable dose among at least 3 dose limiting toxicities (DLT)-evaluable non-homozygous participants.

3. Participants with known active central nervous system (CNS) lesions are excluded. Systemic antineoplastic therapy or investigational agents within 21 days before the first dose of study drug.

4. Radiotherapy within 14 days before the first dose of study drug is not allowed except for limited field radiotherapy for palliative bone pain.

5. For participants where tumor biopsies are required or requested:

- Any known coagulation abnormalities that would contraindicate the tumor biopsy procedure.

- Ongoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel [Plavix®], heparin, or warfarin).

6. Major surgery within 28 days before the first dose of MLN7243.

7. Life-threatening illness unrelated to cancer.

8. Any evidence of active infection or antibiotic therapy within 14 days before the first dose of MLN7243.

9. Known human immunodeficiency virus (HIV) positivity or AIDS-related illness, hepatitis B virus, and hepatitis C virus.

10. Participants whose weight is less than (<) 40 kilogram (kg).

11. History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease.

12. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MLN7243
Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle. Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle. Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Primary Number of Participants With Laboratory Related TEAEs by System Organ Class (SOC) Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Primary Number of Participants With Vital Sign Related TEAEs by Preferred Term (PT) Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Primary Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities Cycle 1 Day 1 up to Cycle 1 Day 11
Primary Number of Participants With Clinically Significant Echocardiogram Abnormalities Cycle 1 Day 2 up to 30 days after last dose of study drug (Cycle 10 Day 41)
Primary Number of Participants With TEAEs Related to Tropinin I and T Baseline up to 30 days after last dose of study drug (Cycle 10 Day 41)
Secondary Ceoi: Plasma Concentration at the End of Infusion for TAK-243 Cycle 1 Day 1 and 11: pre-infusion to end of infusion (up to 10 minutes)
Secondary AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-243 Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Secondary AUCt: Area Under the Plasma Concentration-time Curve Over the Dosing Interval for TAK-243 Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Secondary AUC8: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-243 Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Secondary CL: Total Clearance After Intravenous Administration for TAK-243 Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Secondary Vss: Volume of Distribution at Steady State for TAK-243 Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Secondary Aet: Amount of TAK-243 Excreted Unchanged in Urine Cycle 1 Day 1; Cycle 1 Day 11
Secondary Fet: Percentage of TAK-243 Excreted Unchanged in Urine Cycle 1 Day 1; Cycle 1 Day 11
Secondary Terminal Phase Elimination Half-life (T1/2) for TAK-243 Cycle 1 Day 1 pre-dose and at multiple time points (up to 48 hours) post-dose; Cycle 1 Day 11 pre-dose and at multiple time points (up to 72 hours) post-dose
Secondary Change From Baseline in Immunohistochemistry (IHC) Biomarkers in Tumor Biopsies at Cycle 1 Day 12 (C1D12) as Assessed by Histological Score (H-score) The pharmacodynamics IHC biomarkers included polyubiquitin marker and ubquityl (Ub)-histone H2B marker. H-score was a composite score that comprised of intensity and percentage of staining and was used for assessing the amount of protein or phospho-protein present in a biopsy sample. The composite score obtained by H-score is derived by summing the percentages of cell staining at each intensity multiplied by the weighted intensity of staining (0, 1+, 2+, 3+; where 3+ indicates the strongest staining, 2+ indicates medium staining, 1+ indicates weak staining, and 0 indicates no staining). The composite H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein. Baseline and Cycle 1 Day 12
Secondary Change From Baseline in IHC Biomarkers in Tumor Biopsies at C1D12 as Assessed by Positive Index The pharmacodynamics IHC biomarkers included polyubiquitin marker and Ub-histone H2B marker. Positive index was calculated by taking the number of positive cells over the total number of cells. Baseline and Cycle 1 Day 12
Secondary Percentage of Participants With Best Overall Response Best overall response for participant is best observed post-baseline disease response as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to less than (<) 10 millimeter (mm). Partial Response (PR): at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter; PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study (this includes baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must also demonstrate an absolute increase of at least mm. The appearance of 1 or more new lesions is also considered progression. Baseline up to end of study (approximately 7 months)
Secondary Duration of Response Duration of any response (CR or PR) was defined as the time (in both days and months) from the date of first documented response per the investigator response assessment to the date of first progressive disease after the first documented response or, if the participant discontinues treatment, the date of last disease assessment as per RECIST version 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target and non target) must have reduction in short axis to <10 mm. PR: at least 30% decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. Baseline up to end of study (approximately 7 months)
See also
  Status Clinical Trial Phase
Completed NCT00728468 - A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients Phase 1
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT00768469 - Study Evaluating Safety And Tolerability, Solid Tumor Phase 1
Recruiting NCT04226066 - Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT04908046 - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06464055 - A Study of GQ1010 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06231550 - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors Phase 1
Not yet recruiting NCT05383703 - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor Phase 1
Recruiting NCT05773937 - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors Phase 1
Completed NCT04328506 - Bioequivalency Study of CM082 Tablet in Healthy Volunteers Phase 1
Recruiting NCT05886374 - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT00958724 - Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT05949775 - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors N/A
Completed NCT00884845 - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05277454 - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT Phase 1
Active, not recruiting NCT03792958 - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors Phase 1
Withdrawn NCT00997360 - Study of PKI-179 Administered Orally to Subjects With Solid Tumors Phase 1
Completed NCT04126668 - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers Phase 1
Recruiting NCT05338957 - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03047811 - The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors N/A